Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 1
Submit an article Journal homepage
80
Views
15
CrossRef citations to date
0
Altmetric
Drug Evaluation

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy

Pedro Cahn Fundación Huesped, Angel Peluffo 3932, Buenos Aires, Argentina (C1202ABB). [email protected]
Pages 55-68 | Published online: 02 Mar 2005

Bioliography

  • SAAG M, CAHN P, RAFFI F et al.: A randomized double-blind, multicenter comparison of emtricitabine QD to Stavudine BID. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (2002) (Abstract LB–1).
  • CAHN P, RAFFI F, SAAG M et al.: for the FTC-301 Study Team: virologic efficacy and patterns of resistance mutations in ART-naive patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multi-center clinical trial. 10th Conference on Removiruses and Opportunistic Infections. Boston, MA, USA (2003) (Abstract 606).
  • SANNE I, VAN DER HORST C, SHAW A et al.: Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC). XIV International AIDS Conference. Barcelona, Spain. (2002). (Abstract TuPeB4432).
  • SANNE I, QUINN JB, HARRIS J et al: Genotypic analysis of HIV-1 infected ART-naive patients receiving emtricitabine (FTC) or lamivudine (3TC) in a double blind equivalence trial. XIV International AIDS Conference. Barcelona, Spain. (2002) (Abstract TuPeB4433).
  • PALELLA FJ, DELANEY KM, MOORMAN AC et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. (1998) 338:853–860.
  • HOGG RS, HEATH KV, YIP B et al: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 279:450–454.
  • HOGG R, CAHN P, KATABIRA E et al: Time to act: global apathy towards HIV/ AIDS is a crime against humanity. Lancet (2002) 360(9347):1710–1711.
  • NO AUTHORS LISTED: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with Antiretroviral therapy. HIV Med (2001) 2(4):276–313.
  • PATERSON DL, SWINDELLS S, MOHR J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21–30.
  • BARTLETT JA, DEMASI R, QUINN J, MOXHAM C, ROUSSEAU F: Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS (2001) 15(11):1369–1377.
  • LE MOING V, CHENE G, CARRIERI MP et al: Aproco Study Group Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 16(1):21–29.
  • NIEUWKERK PT, SPRANGERS MAG, BURGER DM et al.: for the ATHENA Project: Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch. Intern. Med. (2001) 161:1962–1968.
  • MANNHEIMER S, FRIEDLAND G, MATTS J, CHILD C, CHESNEY M: for the Terry Beirn Community Programs for Clinical Research on AIDS: The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trails. Clin. Infect. Dis. (2002) 34(8):1115–1121.
  • ENA J, PASQUAU F: Once-a-day highly active antiretroviral therapy: a systematic review. CID (2003). 36:1186–1190.
  • FENG Jet al.: Fine Tuning between anti-viral activity and host toxicity: comparing the incorporation of FTC-TP analogues by HIV-1 RT and human DNA polymerase. Antimicrob. Agents Chemother: (2003) (In press).
  • USP Dictionary of USAN & Intern. Drug Names. The Dialog Corporation, NC, USA (2002):p320.
  • RICHMAN DD: Antiviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Therapy (2001) 6:83–88.
  • WANG LH, BEGLEY J, FENG JY, QUINN J, ROUSSEAU F: Pharmacokinetic and pharmacodynamic characteristics of emtricitabine supports its once daily dosing. XIV International AIDS Conference Barcelona, Spain (2003) (Abstract 4546).
  • SCHINAZI RF: Assessment of the relative potency of emtricitabine and lamivudine. Acquic Immune Defic. Syndr. (2003) 34(2):243–245.
  • ROUSSEAU FS, KAHN JO, THOMPSON M et al: Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). Antimicrob. Chemother. (2001) 48(4):507–513.
  • ROUSSEAU FS, WAKEFORD C, MOMMEJA-MARIN H et al.: A prospective randomized trial of emtricitabine versus lamivudine short term monotherapy in HIV-infected patients. Infect. Dis. (2003) 188(11):1652–1658.
  • Emtriva package insert: Gilead Sciences, July 2003.
  • SAAG M, CAHN P, RAFFI F et al.: for the FTC-301A Study Team: A randomized, double-blind, multicenter comparison of emtricitabine qd to stavudine bid. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (2002) (Abstract 3889).
  • CAHN P, RAFFI F, SAAG Metal: for the FTC-301A Study Team: Virologic efficacy and patterns of resistance mutations in ART-naïve patients receiving combination therapy with daily (qd) emtricitabine compared to twice-daily (bid) stavudine in a randomized, double blind, multicenter clinical trial. 10th Conference on RetroviCuses and Opportunistic Infections. Boston, MA, USA (2003) (Poster 606).
  • RAFFI F, SAAG M, CAHN P et al for the FTC-301A Study Team: A randomized, double-blind, multicenter comparison of emtricitabine qd to stavudine bid in treatment-naïve HIV-infected patients. 2nd International AIDS Socieo, Conference on HIV Pathogenesis and Treatment. Paris, France (2003) (Oral presentation 1432).
  • MOLINA JM, NOE E, RAFFI F et al and the MONTANA Study Group: Once-daily combination therapy with emtricitabine (Ftc), didanosine (Ddi) and efavirenz (Efv) In treatment naïve HIV-infected adults: 3-year follow-up of the montana (Anrs 091) trial. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France (2003) (Abstract 594).
  • MOLINA JM, FERCHALF, RANCINAN C et al.: Once-daily combination of emtricitabine, didanosine, and efavirenz vs continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial (ALIZE-ANRS 99). 10th Conference on Retro viruses and Opportunistic Infections. Boston, MA, USA. (2003) (Abstract 551) .
  • SAEZ-LLORENS X, VIOLARI A, NDIWENI D et al.: Once daily emtricitabine (FTC) in HIV-infected pediatric patients with other antiretroviral agents. 10th Conference on Retrovirus and Opportunistic Infections. Boston, MA, USA. (2003) (Abstract 872).
  • BARTLETT J oN BEHALF OF THE FTC-302 STUDY INVESTIGATORS: Severe Liver Toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. 8th Conference on Retro virus and Opportunistic Infections, Chicago, USA (2001) (Abstract 19).
  • POWDERLY W, MONDOU E, SHAW A et al: Overview of the incidence of symptomatic hyperlactataemia with emtricitabine (FTC). 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France. (2003) (Abstract 737).
  • POWDERLY W, MONDOU E, SHAW A et al: Overview of the Incidence of Symptomatic Hyperlactatemia with Emtricitabine (FTC). Antiviral Therapy (2003). 8(Suppl 1):5389.
  • SANNE I, QUINN JB, HARRIS J et al: Genotypic analysis of HIV-1 infected ART-naive patients receiving emtricitabine (FTC) or lamivudine (3TC) in a double blind equivalence trial. XIV International AIDS Conference. Barcelona, Spain. (2002) (Abstract TuPeB4433).
  • SANNE I, ANDERSON J, KARGL D et al. for THE MKC-401 STUDY TEAM: Evaluation of emtricitabine within a triple NRTI HAART Regimen. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts, American Society for Microbiology Chicago, USA (2003) (Abstract H–868).
  • TURNER D, BRENNER B, ROUTY J, MOISI D, WAINBERG M: Decreased rates of transmission of drug-resistant HIV-1 strains containing the M184V mutation in reverse transcriptase. Program and Abstracts of the XII International HIV Resistance Workshop: Basic Principles and Clinical Implications. Los Cabos, Mexico. (2003) (Abstract 129)
  • WANG L, BLUM M, HUI J, HULETT G, CHITTICK E, ROUSSEAU F: Lack of significant pharmacokinetic interactions between emtricitabine and other nucleoside antivirals in healthy volunteers. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA. (2001) (Abstract A–505).
  • BLUM MR, BEGLEY J, ZONGJ, HILL D, ADDA N, CHITTICK G: Lack of a pharmacokinetic interaction between emtricitabine and tenofovir DF when coadministered to steady state in healthy volunteers. 43rd Intersdence Conference on Antimicrobial Agents and Chemotherapy Chicago, USA. (2003) (Abstract: A–1621).
  • ZONG J, BLUM MR, CHITTICK G, HART R, BROSNAN-COOK M, ADDA N: A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA. (2003) (Abstract A–1620).
  • RAFFI F, SNOW A, BORROTO-ESODA K et al.: Ani-HBV- Activity of Emtricitabine (FTC) in Patients Coinfected with HIV and Hepatitis B Virus. Antiviral Therapy (2003) 8(Suppl 1):5236.
  • MOMMEJA-MARIN H, LEUNG N, GISH R et al: Antiviral activity and incidence of resistance after treatment for two years with emtricitabine in patients with chronic hepatitis B. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego., CA, USA. (2002) (Abstract V–239).
  • CAHN P, RAFFI F, SAAG M et al for the FTC-301A Study Team: Virologic efficacy and patterns of resistance mutations in ART-naïve patients receiving combination therapy with daily (qd) emtricitabine compared to twice-daily (bid) stavudine in a randomized, double blind, multicenter clinical trial. 10th Conference on Removims and Opportunistic Infections. Boston, MA, USA. (2003) (Poster 606).
  • MOLINA JM, FERCHAL F, RANCINAN C et al. for the Montana (Agence Nationale de Recherches sur le SIDA 091) Study Group: Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. Infect. Dis. (2000) 182(2):599–602.
  • WANG L: 35th Inter-Science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA. (1995) (Poster A129).
  • MOLINA JM: 2nd Inernational AIDS Society Paris, France. (2003) (Poster 37).
  • VAN DER HORST C, SANNE I, WAKEFORD C, QUINN J, ROUSSEAU F: Two randomized, controlled, equivalence trials of emtricitibine (FTC) to lamivudine (3TC). 8th Conference on Removiruses and Opportunistic Infections. Chicago, IL, USA. (Abstract 18).
  • WAKEFORD C, SHEN G, HULETT L, QUINN JB, ROUSSEAU F. Long-term efficacy and safety of emtricitabine in HIV+ adults switching from a lamivudine containing HAART regimen. 10th Conference on Removiruses and Opportunistic Infections. Boston, MA, USA. (2003) (Abstract 550).
  • SANNE I, ANDERSON J, KARGL D et al. for the MKC-401 study team: Evaluation of emtricitabine within a triple NRTI HAART Regimen. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA. (2003) (Abstract H–868).
  • LANGE CG, PATTERSON BK, HARNISH B et al.: Lymphoproliferative responses to HIVp24 in chronically HIV-1 infected patients treated with HAART reflect low-level viral replication but not an improvement in indices of immune phenotype or function. 10th Conference on Retrovimses and Opportunistic Infections Boston, MA, USA. (2003) (Abstract 345). Further Reading:
  • DE CLERCQ E. New developments in anti-HIV chemotherapy. Biochim. Biophys. Acta (2002) 1587(2-3):258–275.
  • MOLINA JM, FERCHAL F, RANCINAN C et al.: Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.' Infect. Dis. (2000) 182(2):599–602.
  • PAPATHEODORIDIS GV, DIMOU E, PAPADIMITROPOULOS V: Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am. .1 Castroenterol (2002) 97(7):1618–1628.
  • FENG JY, SHI J, SCHINAZI RF, ANDERSON KS: Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB 1(1999). 13(12):1511–1517.
  • GISH RG, LEUNG NW, WRIGHT TL et al.: Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob. Agents Chemothei: (2002) 46(6):1734–1740.
  • DARQUE A, VALETTE G, ROUSSEAU F et al.: Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother: (1999) 43(9)2245–2250.
  • LIU H, GOLIN CE, MILLER LG et al.: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann. Intern. Med. (2001) 134(10):968–977.
  • VOLMINK J, MATCHABA P, GARNER P: Directly observed therapy and treatment adherence. Lancet. (2000) 355(9212):1345–50.
  • BANGSBERG DR, MUNDY LM, TULSKY JP: Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am. I Merl (2001). 110(8):664–666.
  • KIRKLAND LR, FISCHL MA, TASHIMA KT et al.: Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin. Infect. Dis. (2002). 34(4):511–518.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.